We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Dollars in the pipeline

8 Oct 2010 By Pierre Briancon

The U.S. biotech says the French pharma group last month indicated it might be willing to bid up to $80 a share. Sanofi denies ever mentioning a price range, and is sticking with its hostile, $69ashare cash offer. But it can afford to pay more, and probably will.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)